SEC Form 4 · accession 0001652410-26-000016
Xeris Biopharma Holdings, Inc. · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Beth Hecht
Officer — See Remarks
Period of report
Aug 3, 2026
Accepted (ET)
Aug 4, 2026 · 5:16 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001867096
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 3, 2026 | S | 16,666 | $8.0135 | D | 1,144,462 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.870 to $8.140, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Remarks
Chief Legal Officer and Corporate Secretary